Loading
A Vietnamese study of whether the SPOT-MAS blood test can help sort out which people with worrying symptoms have one of five common cancers.
K-ACCELERATE (NCT06391749) is an observational study sponsored by Gene Solutions with University of Medicine and Pharmacy at Ho Chi Minh City. Its primary objective is the performance of SPOT-MAS in detecting cancer in symptomatic people; a secondary objective is its feasibility as a primary-care triage test.
The registry record, read on 29 October 2026, gives its status as enrolling by invitation, with an estimated 1,000 participants, a start on 30 July 2024 and primary completion expected in July 2026.
Shares Gene Solutions, SPOT-MAS, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Gene Solutions, SPOT-MAS, Multi-cancer early detection (MCED).
Shares Gene Solutions, SPOT-MAS, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/